An additional decline in tumor size and CA19-9 was apparent at initiation of trastuzumab deruxtecan monotherapy while the patient was concomitantly receiving immunotherapy, further supporting the hypothesis that the patient's tumor could have been sensitive to HER2 inhibition. This evidence concerns the gene ERBB2 and neoplasm.